Mode
Text Size
Log in / Sign up

Narrative review proposes redox-guided framework for vitamin D, myo-inositol, and melatonin in PCOSResearchers propose new PCOS framework using vitamin D and melatonin

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that combined vitamin D, myo-inositol, and melatonin supplementation requires standardized future trials.

This narrative review evaluates the potential of a combined supplementation strategy involving vitamin D, myo-inositol, and melatonin for patients with polycystic ovary syndrome. The scope of the article focuses on synthesizing current evidence to address heterogeneity in outcomes related to ovulatory function, insulin resistance indices, and oxidative stress biomarkers. The authors note that existing trials vary significantly in their dosing regimens, treatment duration, and patient phenotype stratification, which limits direct comparisons. Consequently, the review does not provide pooled effect sizes or specific statistical data such as confidence intervals or p-values.

The authors propose a redox-guided, phenotype-aware framework to guide the design of future clinical trials. This approach aims to standardize variables that currently contribute to heterogeneity in reported results. The review explicitly avoids claiming causal relationships for the proposed 'bioactive cocktail' as this remains a hypothesis. Specific details regarding dosing, duration, and phenotype stratification are not specified in this text but are acknowledged as sources of variation in the literature.

Practice relevance is framed cautiously, suggesting that clinicians should await further standardized trials before adopting this combination as a standard of care. The review does not report specific adverse events, serious adverse events, discontinuations, or tolerability data. Funding sources and conflicts of interest are not reported. The certainty of the findings is limited by the lack of primary trial data and the reliance on a narrative synthesis of heterogeneous studies.

Living with polycystic ovary syndrome often means dealing with issues that affect ovulation and insulin. Many people search for better ways to manage these symptoms without heavy medication. We need clear answers about what actually works for the body. Researchers are looking for new strategies to help patients feel better.

This narrative review looks at a specific mix of supplements. It examines vitamin D, myo-inositol, and melatonin together. The goal is to see how they impact ovulatory function and insulin resistance indices. Researchers also looked at oxidative stress biomarkers. They analyzed existing data to find patterns.

The authors suggest a new way to test these combinations in future research. They call it a redox-guided, phenotype-aware framework. This means trials should match treatments to specific patient types. They want to understand the biology better. This approach aims to reduce confusion in results.

The data is not perfect. Existing studies used different doses and lasted different lengths of time. This makes it hard to say exactly how well the mix works for everyone right now. The text did not report safety signals clearly. We cannot confirm if the combination is safe for all users.

What this means for you:
A new framework suggests testing vitamin D, myo-inositol, and melatonin together for PCOS, but results vary.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine–metabolic disorder in which reproductive dysfunction coexists with insulin resistance, chronic low-grade inflammation, and heightened oxidative stress (OS). Increasing evidence indicates that these abnormalities are not independent phenomena but components of a self-perpetuating redox-endocrine network that sustains hyperandrogenism, anovulation, and metabolic impairment. This review critically synthesizes experimental, translational, and clinical data to examine whether vitamin D, myo-inositol, and melatonin, three widely used but often studied in isolation bioactives, can act synergistically as a mechanistically coherent ‘bioactive cocktail’ in PCOS. Vitamin D modulates inflammatory tone and steroidogenic signaling through vitamin D receptor-dependent transcription and immune–metabolic crosstalk; myo-inositol restores insulin signaling via inositolphosphoglycan second-messenger pathways, thereby attenuating hyperinsulinemia-driven androgen excess; and melatonin exerts pleiotropic effects on mitochondrial function, circadian regulation, and redox balance. Therefore, these agents converge on shared molecular hubs, including NF-κB, Nrf2, PI3K/Akt, and AMPK, linking OS reduction with endocrine and metabolic recalibration. The review further integrates emerging insights into gut microbiota-adipokineinteractions, highlighting how dysbiosis and altered adipokine profiles amplify oxidative and hormonal disturbances, and how these bioactives may counteract such system-level disruptions. While existing clinical trials report improvements in ovulatory function, insulin resistance indices, and OS biomarkers, outcomes remain heterogeneous due to differences in dosing, duration, and phenotype stratification. We propose a redox-guided, phenotype-aware framework for future trials, emphasizing biomarker-anchored outcomes and systems-level integration. If validated, combined vitamin D, myo-inositol, and melatonin supplementation may represent a precision nutraceutical strategy that targets the pathogenic core of PCOS rather than its isolated clinical manifestations.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.